Our tenth Insight Session explored ibogaine through clinical, cultural, and consciousness-focused lenses, examining why the compound continues to occupy a unique position within the psychedelic field.
Lia Mix sits down with Dr. Leith States and Ryan Roberts to discuss what the federal psychedelic executive order means in practice, where it may accelerate progress, and what still stands between policy signal and real patient access.
Lia Mix sits down with Floris Wolswijk, founder of Blossom, to discuss how psychedelic research can be made more usable for the people shaping the field.
Lia Mix and Britt Rollins discuss insurance, infrastructure, and what it will take to scale psychedelic care safely.
Welcome and Introduction of Melissa Lavasani Lia Mix: Hello, everyone, and welcome. I am Lia Mix, the CEO of Delphi, and we are excited to have you for our monthly insight session. Today, we welcome Melissa Lavasani, the founder and CEO of the Psychedelic Medicine Coalition (PMC). PMC is the only Washington, D.C.-based nonprofit dedicated to advancing psychedelic-assisted therapies at the federal level. A nationally recognized policy leader, Melissa authored and led the passage of Washington, D.C.’s Initiative 81, the Entheogenic Plant and Fungus Policy Act of 2020. This passed with 76 percent voter approval, motivated by her personal experience using psychedelic medicines to recover from severe postpartum depression. Under her leadership, PMC has built bipartisan support in Congress and advanced key federal legislation through the Congressional Psychedelics Advancing Therapies (PATH) Caucus. This includes the Innovative Therapies Centers for Excellence Act and the Expanding Veterans Access to Emerging Treatments Act.
In this Delphi Insight Session, Dr Leith States discusses psychedelic-assisted therapies and ibogaine and how they can impact public health.
In this Delphi Insight Session, Lia Mix shares her journey with trauma and healing, and how Delphi and IHPI are advancing Ibogaine therapy.
Kate Reynolds from Rocky Mountain Poison and Drug Safety (RPMDS) discusses how NSIHT tracks real world psychedelic use nationwide.
Join Lia Mix, CEO of Delphi, and Floris Wolswijk, Senior Policy and Research Partner at Delphi, for the third Delphi Insight Session on reimbursement pathways for psychedelic therapies in Europe.
The second Delphi Insight Session features a conversation with Tyler Norris on the integration of psychedelics into the broader healthcare system, the challenges, and roadmap towards making this integration happen.
